Tellgen’s 20‑Cent Surge: How China’s “Fifteen‑Five” Plan Fuels Biotech Boom
Tellgen’s 20‑cent limit‑up showcases China’s biotech surge, backed by the “Fifteen‑Five” plan. Discover how its diversified IVD portfolio drives growth and investor interest.
3 minutes to read